To the best of our knowledge, it has never been studied in a clinical setting whether there is an association between EGFR, RANKL, RANK and OPG gene expression in the tumor and presence of bone metastases in patients with NSCLC. This evidence concerns the gene TNFRSF11A and neoplasm.